Poolbeg Pharma PLC Announces Result of AGM

Rhea-AI Summary

Poolbeg Pharma (AIM:POLB, OTCQB:POLBF) held its Annual General Meeting on April 4, 2022, where all resolutions received over 99.9% approval. The company focuses on developing innovative products in the infectious disease sector using a capital light clinical model, aiming for faster and cost-effective development compared to traditional biotech approaches. Poolbeg targets the rapidly expanding infectious disease market projected to exceed $250bn by 2025, drawing on insights from over 20 years of human challenge trials.

Positive

• All AGM resolutions passed with over 99.9% approval.
• Targets a growing infectious disease market expected to exceed $250bn by 2025.
• Utilizes a capital light clinical model for efficient product development.

Negative

• None.

News Market Reaction – POLBF

%

1 alert

% News Effect

On the day this news was published, POLBF declined NaN%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

LONDON, UK / ACCESSWIRE / April 4, 2022 / Poolbeg Pharma (AIM:POLB, OTCQB:POLBF, 'Poolbeg' or the 'Company') a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces that at the Annual General Meeting held at 11:00am today, all resolutions were duly passed with in excess of 99.9% approval.

-Ends-

Enquiries

Poolbeg Pharma Plc Jeremy Skillington, CEO Ian O'Connell, CFO	+44 (0) 207 183 1499
finnCap Ltd (Nominated Adviser & Joint Broker) Geoff Nash, James Thompson, Charlie Beeson, Richard Chambers, Sunila de Silva (ECM)	+44 (0) 207 220 0500
Arden Partners PLC (Joint Broker) John Lewellyn-Lloyd, Louisa Waddell	+44 (0) 207 614 5900
J&E Davy (Joint Broker) Anthony Farrell, Niall Gilchrist	+353 (0) 1 679 6363
Instinctif Partners Melanie Toyne Sewell, Rozi Morris, Tim Field	+44 (0) 20 7457 2020 poolbeg@instinctif.com

About Poolbeg Pharma

Poolbeg Pharma is a clinical stage infectious disease pharmaceutical company, with a capital light clinical model which aims to develop multiple products faster and more cost effectively than the conventional biotech model. The Company, headquartered in London, is led by a team with a track record of creation and delivery of shareholder value and aspires to become a "one-stop shop" for Big Pharma seeking mid-stage products to license or acquire.

The Company is targeting the growing infectious disease market. In the wake of the COVID-19 pandemic, infectious disease has become one of the fastest growing pharma markets and is expected to exceed $250bn by 2025.

With its initial assets from Open Orphan plc, an industry leading infectious disease and human challenge trials business, Poolbeg has access to knowledge, experience, and clinical data from over 20 years of human challenge trials. The Company is using these insights to acquire new assets as well as reposition clinical stage products, reducing spend and risk. Amongst its portfolio of exciting assets, Poolbeg has a small molecule immunomodulator for severe influenza (POLB 001); a first-in-class, intranasally administered RNA-based immunotherapy for respiratory virus infections (POLB 002); and a vaccine for Melioidosis (POLB 003). The Company is also developing an oral vaccine delivery platform and is progressing two artificial intelligence (AI) drug discovery programmes to accelerate the power of its human challenge model data and biobank.

For more information, please go to www.poolbegpharma.com or follow us @PoolbegPharma.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Poolbeg Pharma PLC

View source version on accesswire.com:
https://www.accesswire.com/695825/Poolbeg-Pharma-PLC-Announces-Result-of-AGM

FAQ

What were the results of Poolbeg Pharma's AGM on April 4, 2022?

All resolutions at Poolbeg Pharma's AGM were approved with over 99.9% approval.

What is the focus of Poolbeg Pharma in the pharmaceutical market?

Poolbeg Pharma focuses on developing products in the infectious disease sector.

What is the projected size of the infectious disease market by 2025?

The infectious disease market is projected to exceed $250bn by 2025.

What does Poolbeg Pharma's capital light clinical model entail?

It aims for faster and more cost-effective product development compared to traditional biotech models.